Paris, France—Progress in genotyping patients with rheumatoid arthritis (RA) suggests that the amino acid valine at position 11 of the HLA-DRB1 gene appears to be the strongest independent genetic determinant of radiographic damage in this disease.
Biomarker Panel an Objective Measure of Disease Activity, Treatment Response in Rheumatoid Arthritis
By Wayne Kuznar A panel of disease biomarkers can measure changes in disease activity in response to a range of therapies for rheumatoid arthritis (RA), researchers announced at the 2012 meeting of the American College of Rheumatology (ACR).
By Phoebe Starr Ongoing research using DNA sequencing is being used to examine how the microbiome in the oral cavity and in the gastrointestinal tract affects autoimmune diseases such as rheumatoid arthritis (RA), scientists explained at the 2012 meeting of the American College of Rheumatology.
By Phoebe Starr San Diego, CA—“This is an exciting time for treatment of rheumatoid arthritis [RA], with many new therapies. But the question is where do we go from here for future therapies, and what have we learned from past failures,” Arthur F. Kavanaugh, MD, Director, Center for Innovative Therapy, University of California, San Diego, La Jolla, told listeners at the 2013 American College of Rheumatology meeting.
A recent review evaluating currently available data on rheumatoid arthritis (RA) diagnosis, prognosis, and prediction of response to therapy, highlights the potential of gene expression profiling in understanding RA biology, patient management, and personalized care.
Assessing genetic risk can improve outcomes By Charles Bankhead The ability to predict who is at risk for developing rheumatoid arthritis (RA) improved significantly with a new model based on a combination of genetic risk scores, environmental factors, and gene–environment interactions (GEIs), according to an analysis of 2 large cohort studies.
By Sy Schlager, MD, PhD
Belimumab (Benlysta) has recently been approved in the United States for the treatment of systemic lupus erythematosus (SLE), with a specific indication for use in adult patients with active, autoantibody-positive disease who are currently receiving standard therapies. However, the optimal use of this agent in SLE has not been well defined.
Page 1 of 3
Results 1 - 10 of 23
Results 1 - 10 of 23